source
- Lilly’s EloraTZP combo shows superior weight loss and glucose control, moves to Phase 3Eli Lilly reported that its experimental combination, EloraTZP, which pairs an amylin agonist with the approved obesity drug Zepbound, met all primary and secondary goals in a mid‑stage study of ad…
- Bristol Myers revises Phase 3 fibrosis trial after liver safety events, including a deathBristol Myers Squibb announced a change to its late-stage Phase 3 "Aloft" trial of the experimental pulmonary fibrosis drug admilparant. The amendment adds closer monitoring for liver-related adve…BioPharma Dive · 1mo agoNegative readoutNegative